arrow
K

Kyoichi Kaira

Saitama Medical University
H指数:54
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B)

比较蒽环类药物联合铂类药物与其他铂类为基础的方案作为初治胸腺瘤的一线化疗:一项回顾性队列研究(NEJ023B)

2026-05-120
PRE
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
2025-11-011
PRE
The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%

PD-L1表达为1%至49%的NSCLC患者中,抗生素使用对ICI联合化疗与化疗的影响

2024-12-010
PRE
Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study

II期临床试验:阿替利珠单抗联合卡铂和紫杉醇治疗转移性或复发性胸腺癌患者:Marble研究

2024-12-010
PRE
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1%to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者预后预测的影响:化疗与化疗免疫治疗的多中心回顾性研究

2024-10-250
OA
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)

前瞻性观察研究,以探索预测布格替尼对ALK基因重排非小细胞肺癌的疗效和安全性的基因和蛋白质: ABRAID研究的研究方案 (WJOG11919L)

2024-01-270
OAAI